TA' XBIEX, Malta, Oct. 2, 2026 /PRNewswire/ -- Betsson Group today announced the launch of the Betsson Foundation, a registered public benefit foundation that brings together and supports the Group's charitable, community and sports-related initiatives under one organisation.

For many years, Betsson Group has contributed to a wide range of organisations and local communities across its markets and office locations, from employee-led fundraising and grassroots projects to community and CSR initiatives developed through our partnerships with leading football clubs and athletes.

The launch of the Betsson Foundation marks the next step in the Group's long-standing commitment to creating positive impact. The Foundation will serve as the central organisation for coordinating and scaling Betsson Group's social impact activities, working closely with employees, partners and local organisations across Betsson's markets. By bringing together existing and new initiatives under a shared framework, the Foundation will strengthen collaboration and knowledge sharing, while increasing the long-term impact of these initiatives.

"Sport and community engagement have long been part of Betsson's DNA. The launch of the Betsson Foundation strengthens our ability to support the people, programmes and organisations making a positive difference in our communities. It also gives us the opportunity to work even more closely with our clubs and athlete partners to connect the power and reach of sport with meaningful community initiatives", said Jesper Svensson, CEO of Betsson Operations.

"Through the Betsson Foundation, we aim to create lasting positive impact by supporting worthy causes, fostering long-term partnerships, and bringing together initiatives that strengthen communities across our locations", said Jonna Danlund, Director of ESG.

Sport will remain a central focus of the Foundation's work, reflecting Betsson's long-standing engagement and partnerships across the sporting community. The Foundation will seek to leverage Betsson's global sports partnerships to expand the reach and impact of its initiatives.

As the Foundation develops, it will continue to build on existing partnerships while identifying new opportunities to support communities across Betsson's markets. One recent example is the Foundation's support for Boosting Up, a five-year programme in Peru that supports 22 participants from a school in Lima through football, English-language education and nutritional support.

The Betsson Foundation has been incorporated in Malta as a separate legal entity and operates under a governance framework comprising the founding company, a Board of Administrators, and a Supervisory Council. The structure provides oversight and accountability while supporting the Foundation in pursuing its philanthropic objectives and managing its activities responsibly and in accordance with applicable legal requirements.

For more information, please contact: 

Robin Olenius, Head of PR, Betsson Group

email: [email protected]

About Betsson Group

Originally founded in 1963, Betsson Group is a global leader in the entertainment industry, offering multiple services to consumers, including gaming, betting and infotainment. With proprietary technology across its diverse product offering, Betsson serves customers with a B2C offering and other gaming operators as a B2B supplier. The company's vision is to provide the best customer experience in the industry. Sustainability is an integrated part of Betsson's strategy, as taking responsibility for customers, employees and communities is a prerequisite for running a sustainably successful business.

Betsson Group employs around 3,000 people in Europe, South America, Asia and North America. The parent company, Betsson AB, is listed on Nasdaq Stockholm. Read more on: www.betssongroup.com and www.betssonab.com

About Betsson Foundation

Betsson Foundation is a registered public benefit foundation that brings together and supports Betsson Group's charitable, community and sports-related initiatives under one organisation. For more information, please visit: www.betssonfoundation.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

China's First Modern University Celebrates 131 Years of Excellence

TIANJIN, China, Oct. 1, 2026 /PRNewswire/ -- On October 2, 2026, Tianjin University (TJU), China's first modern university, celebrates its 131st anniversary. This milestone highlights TJU's enduring legacy as a steadfast contributor to global innovation and social progress, consistently rising to meet the world's most pressing challenges with visionary foresight and profound dedication.

Cultivating Visionaries for a New Era

TJU's 131st year is defined by a profound commitment to cultivating visionary talent. The university, as the lead institution of the National Working Group on Emerging Engineering Education, has unveiled "TJU Plan 3.0", a forward-looking framework for emerging engineering education designed to nurture future-ready talent.

Aligning with the evolution of future industries, TJU has strategically positioned itself across 11 frontier fields, including artificial intelligence and embodied intelligence. Furthermore, the university has pioneered China's first undergraduate majors in brain-computer science and technology, as well as biomanufacturing.

To nurture top-tier young scholars, TJU introduced the "U35 Plan". This initiative fast-tracks exceptional researchers under the age of 35 to full professorships, recognizing future potential and fostering a dynamic, youth-led research environment where brilliant minds can thrive.

From Laboratory to Lifesaving Impact

The convergence of national-level talents, industry experts, and leading enterprises has created a robust innovation ecosystem at TJU. This ecosystem has yielded landmark achievements. In medical technology, the "Shengong-Shengao" system became China's first approved brain-computer interface (BCI) medical device for diagnosing cognitive impairment. Developed by a team led by Professor Liu Xiuyun, the system reduces diagnosis time for conditions like hydrocephalus from days to just 30 minutes. Additionally, more than 20 "Shengong" series devices have successfully transitioned from the laboratory to clinical wards, delivering tangible benefits to thousands of patients.

From high-precision measurement and energy storage technologies to national platforms like the National Facility for Earthquake Engineering Simulation, the ethos of "aiming for the highest scientific peaks while remaining deeply grounded in real-world needs" permeates the campus. This commitment was recognized in 2025, when TJU researchers were lead contributors to five National Science and Technology Awards.

Furthermore, the university's academic excellence is recognized globally, with three disciplines—Chemistry, Engineering, and Materials Science—ranked in the global top 1‱ according to the Essential Science Indicators (ESI).

With a focus on strategic clusters, a talent-driven approach, and an unwavering commitment to human well-being, Tianjin University at 131 is not just celebrating its past—it is actively engineering a better future.

SOURCE Tianjin University

Share this article

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28–October 2, 2026, in Milan, Italy (EASD 2026). ASC36_35FDC is a once-monthly to once-quarterly fixed-dose combination injection of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist. The study was presented in a short oral discussion. The data demonstrated that ASC36_35FDC exhibited a greater weight-loss trend than eloralintide/tirzepatide or MET-233i/tirzepatide co-formulations in a diet-induced obesity (DIO) rat model, as well as excellent formulation stability. Furthermore, once-weekly oral tablet formulation of ASC36_35FDC has been developed by the Company.

Key Highlights

Robust Weight-Loss: Demonstrating Potential Synergistic Effects in Preclinical Models

In both DIO rat and non-human primate (NHP) models, ASC36_35FDC showed greater additional reductions in body weight and food intake compared with ASC35 monotherapy, suggesting a potential synergistic effect of the combination.

In the DIO rat model, ASC36_35FDC administered at 5 nmol/kg_8 nmol/kg once every two days for a total of seven doses demonstrated substantial weight-loss. On Day 14, under the same dosing regimen, body weight decreased by 12.5% with the eloralintide/tirzepatide co-formulation, 16.8% with the MET-233i/tirzepatide co-formulation, and 24.8% with ASC36_35FDC, a 98% and 47% greater relative reduction in body weight, respectively. Cumulative food intake was also substantially lower in the ASC36_35FDC group compared to the two comparator groups.

Excellent Chemical and Physical Stability: No Evidence of Fibrotic Aggregation

Long-term formulation stability is critical for peptide-based therapeutics. Under simulated storage conditions (200 rpm, 25°C, 168 hours), no fibril-induced aggregation was observed for ASC36_35FDC across different concentrations, vehicles, or pH conditions. In contrast, cagrilintide exhibited substantial fibrotic aggregation under the same conditions. These findings demonstrate the excellent chemical and physical stability of ASC36_35FDC and provide a strong foundation for further clinical development and potential large-scale manufacturing.

Pharmacokinetic Profile: Potential for Once-Monthly to Once-Quarterly Dosing

In NHPs, the pharmacokinetic (PK) profile of ASC36_35FDC was comparable to that observed following administration of ASC36 or ASC35 alone. The observed half-life of ASC36 and ASC35 demonstrated in ASC36_35FDC were as long as 781 hours(approximately 33 days) and 721 hours (approximately 30 days), respectively, supporting once-monthly and the potential for once-quarterly subcutaneous administration in humans. This ultra-long-acting profile has the potential to improve treatment convenience and patient adherence, offering a more convenient therapeutic approach for chronic weight management.

Summary and Outlook

ASC36_35FDC is an internally developed combination therapy leveraging Ascletis' proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. By combining an amylin receptor agonist with a GLP-1R/GIPR dual agonist, ASC36_35FDC is designed to leverage the complementary effects of these two therapeutic mechanisms. The preliminary preclinical data demonstrate promising activity across body-weight reduction, appetite suppression, formulation stability, and pharmacokinetic properties, supporting the potential of ASC36_35FDC as a best-in-class therapeutic candidate.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once monthly subcutaneously and once daily orally, and ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo

ICR Healthcare

443-231-0505 (U.S.)

[email protected]

Ascletis Pharma Inc. PR and IR Teams

+86-181-0650-9129 (China)

[email protected]

[email protected] 

SOURCE Ascletis Pharma Inc.

Share this article

New Amen Clinics research finds several distinct brain-function patterns in postpartum depression, differing significantly from those seen in major depression.

COSTA MESA, Calif., Oct. 2, 2026 /PRNewswire/ -- The high-profile Lindsay Clancy case has brought renewed attention to the serious mental health challenges women can face after giving birth.

Clancy, a Massachusetts mother who killed her three young children in 2023, had sought psychiatric help and received numerous medications in the months before the tragedy. Her defense argued that she was experiencing postpartum psychosis and had not received appropriate treatment, while prosecution experts disputed this claim.

It has sparked a critical conversation about postpartum mental health care and how biology factors into psychiatric diagnosis and treatment. For example, are there functional brain differences between postpartum depression vs depression?

Now, new research from Dr. Daniel Amen and colleagues, currently in preparation for publication, is using brain SPECT imaging to more fully understand the underlying brain function patterns associated with postpartum depression (PPD). Using SPECT, the researchers examined whether women diagnosed with PPD share a common brain pattern and whether their patterns differ from those seen in depression more broadly.

Dr. Amen and colleagues reviewed brain SPECT scans from 58 women with postpartum depression and compared them with scans from 26,077 people with major depression. The scans were grouped into six brain-function patterns, including hyperfrontal/anterior cingulate cortex (ACC), limbic, hypofrontal, toxic/diffuse low perfusion, brain trauma/acquired injury, and mixed patterns.

Key Study Statistics

- Nearly 40% of women with PPD showed a hyperfrontal/ACC pattern, compared with 19.4% of those with major depression.

- Limbic patterns were also about twice as common: 24.1% in PPD versus 12% in major depression.

- Hypofrontal patterns appeared in 15.5% of PPD patients versus 6.8% in major depression.

- One of the most striking differences involved the brain trauma/acquired injury pattern: it appeared in 25.3% of the major depression group but just 1.7% of the postpartum depression group.

These new research findings from Amen Clinics reinforce an important point: The same psychiatric diagnosis can encompass different patterns of brain function. Understanding those differences may help explain why women with similar symptoms can respond differently to treatment and why a more individualized approach to care may be beneficial.

The new Amen Clinics research adds to a growing body of evidence suggesting that psychiatric diagnoses based on symptoms alone may not tell the whole story. Women with postpartum depression in the study showed several distinct patterns of brain function, and those patterns differed significantly from those seen in the much larger major depression group.

At Amen Clinics, brain SPECT imaging is not used in isolation to diagnose postpartum depression or determine treatment. It is one component of a comprehensive evaluation designed to provide clinicians with more information about the individual patient.

The emerging postpartum depression research suggests why that additional information may matter: The same symptoms and diagnostic labels can be associated with different patterns in the brain, and understanding those differences may ultimately help support more individualized care.

Read the full Amen Clinics article on postpartum depression vs. depression.

About Amen Clinics

For decades, Amen Clinics has used brain SPECT imaging as part of a comprehensive evaluation of mental health conditions.

Based on a database of nearly 300,000 SPECT scans, Amen Clinics clinicians have identified certain brain patterns, or brain dysfunction, associated with different mental health conditions.

Media Contact

Jordyn Dean

Publicist, Amen Clinics

[email protected]

SOURCE Amen Clinics, Inc.

Share this article

Tight Poker Announces Free Poker Tournaments With $3,000 in Monthly Prizes

Weekly $500 tournaments began on September 19 and occur weekly, with top finishers qualifying for a $1,000 monthly championship.

TORONTO, Oct. 2, 2026 /PRNewswire/ -- Tight Poker has launched a new series of free online poker tournaments, offering players $3,000 in recurring Bitcoin (BTC) prizes each month.

With the next event taking place October 3, Tight Poker will host free $500 No-Limit Texas Hold'em tournaments every Saturday. The top 27 finishers each week will qualify for a $1,000 monthly championship.

Each weekly tournament is free to enter with a tournament ticket and is limited to 200 players.

How the Tournaments Work

Tight Poker will hold a $500 tournament every Saturday, with registration opening on the morning of each event.

Players can earn one weekly tournament ticket by logging in to their Tight Poker account. A ticket is required to register for that Saturday's tournament.

The top 27 finishers in each weekly tournament will receive a ticket to the monthly championship. The championship will take place on the final Saturday or Sunday of each month and feature a $1,000 Bitcoin prize pool.

With four $500 weekly tournaments and a $1,000 monthly championship, Tight Poker will award $3,000 in Bitcoin prizes each month.

The tournament schedule includes:

- Weekly tournaments: Every Saturday, free to enter with a ticket, with a $500 Bitcoin prize pool.

- Monthly championship: Held at the end of each month, free to enter for qualified players, with a $1,000 Bitcoin prize pool.

Tournament Format

The weekly and monthly events will use a turbo-style No-Limit Texas Hold'em format designed to be completed in approximately one to two hours.

Each tournament features:

- 800-chip starting stacks

- Five-minute blind levels

- A maximum field of 200 players for weekly tournaments

The next weekly tournament will take place on October 3rd, with additional events scheduled every Saturday.

How to Enter

Players must create or log in to a Tight Poker account and complete account verification before participating.

To enter, players need to:

- Create or log in to a Tight Poker account.

- Complete account verification.

- Simply log in during the week to receive a weekly tournament ticket.

- Register once tournament registration opens.

- Enter the Saturday No-Limit Texas Hold'em tournament.

- Finish in the top 27 to qualify for the monthly championship.

Registration remains open until the tournament begins, subject to the 200-player capacity.

Only one account is permitted per player. Players found to have created multiple accounts may be banned from participating and withdrawing tournament winnings.

Prizes and Withdrawals

All tournament prizes will be paid in Bitcoin. At the end of each tournament, winnings will be credited to eligible players' Tight Poker accounts. Players can request a withdrawal through the Cashier using their Bitcoinwallet address.

Full tournament rules, schedules and entry information are available at TightPoker.com.

About Tight Poker

Tight Poker is an online poker resource covering poker strategy, tournaments, industry news and educational content for players. The site provides guides and expert insights designed to help players improve their game and stay informed about developments across online and live poker.

Media Contact:

Tight Poker [email protected] 

SOURCE Tight Poker

Share this article

Mysk Luxury Hotel - the First in Saudi Arabia - is Built for Durability with Penetron Technology

The ceremonial September 2026 opening of the Mysk Al Wadi Jeddah Hotel in Jeddah, Saudi Arabia is the first Mysk luxury hotel brand location in the Kingdom. PENETRON ADMIX, a crystalline waterproofing admixture, was specified for all below-grade concrete structures to protect against high groundwater levels.

ORLANDO, Fla., Oct. 2, 2026 /PRNewswire/ -- Saudi Arabia's most important Red Sea commercial port and main embarking point for Muslim pilgrims journeying to the holy cities of Mecca and Medina, Jeddah is a city of around 5.5 million people. Thanks to the steady influx of travelers, it continues to build new hotels, shopping centers, and other infrastructure.

The Mysk Al Wadi Jeddah Hotel is located in the Obhur district, near the Red Sea close to the Jeddah Corniche. The four-star hotel has 90 rooms on five floors. The hotel also features a restaurant, a café, meeting rooms, a kids' club, fitness center and rooftop pool.

"Due to the depth of the construction site excavation, the project's general contractor, Faraj Abdulkarim Est, needed a robust concrete waterproofing solution to keep the below-grade concrete structures dry," recounts Sam Annous, Managing Director of Penetron Saudi Arabia. "We saw the below-grade concrete structures would be exposed to the high groundwater levels at the construction site. Also, the hotel's close proximity to the Red Sea made resilience against the chloride-rich environment a priority as well."

PENETRON ADMIX, a crystalline waterproofing admixture, was added to the concrete mix to treat over 2,000 m3 (2,620 yds3) of concrete used for the hotel's raft foundation, retaining walls, parking floors, and water-retaining structures, including the drinking water tanks and swimming pool. PENEBAR SW-45A, a swellable waterstop strip, was also specified to permanently seal the construction joints.

The active ingredients in PENETRON ADMIX SB react in a catalytic reaction to the moisture in concrete to generate a non-soluble crystalline network throughout the pores and capillary tracts of the concrete. This network permanently seals the concrete against the penetration of water or liquids from any direction, even under the constant saltwater exposure prevalent at the Jeddah construction site.

"Thanks to our technical support and quick follow-up, the customer was very pleased with the support service and ultimately, the performance of the Penetron products," adds Sam Annous.

The Penetron Group is a leading manufacturer of specialty construction products for concrete waterproofing, concrete repairs, and floor preparation systems. The Group operates through a global network, offering support to the design and construction community through its regional offices, representatives, and distribution channels.

For more information on Penetron waterproofing solutions, please visit penetron(dot)com or Facebook(dot)com/ThePenetronGroup, email CRDept(at)penetron(dot)com or contact the Corporate Relations Department at 631-941-9700.

SOURCE The Penetron Group

Share this article

Skanska signs additional contract for new hospital in Fort Myers, Florida, USA, for USD 60M, about SEK 560M

STOCKHOLM, Oct. 2, 2026 /PRNewswire/ -- Skanska has signed an additional contract with Lee Health for the construction of a new hospital and medical office building in Fort Myers, Florida, USA. The additional contract is worth USD 60M, about SEK 560M, which will be included in the US order bookings for the third quarter of 2026.

The full project contract was amended to include interior build-out finishes, and mechanical, electrical and plumping work associated with the West Bed Tower expansion. The full project scope includes constructing an approximately 38,600 square-meter (416,000-square-foot), five-story hospital, a central energy plant, and an approximately 11,600 square-meter (125,000-square-foot) medical office building which includes an ambulatory surgery center.

Construction began in June 2024 and is scheduled for completion in May 2028.

CONTACT:

For further information please contact:

Jessica Wheeler, Communications Director Southeast, Skanska USA, tel +1 919 717 3429

Andreas Joons, Press Officer, Skanska AB, tel +46 76 870 75 51

Direct line for media, tel +46 (0)10 448 88 99

This and previous releases can also be found at www.skanska.com/group.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE Skanska

Share this article

FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR), Which Has Proposed to Acquire FFAI's EAI Robotics Business, Highlights FFAI's EAI Robotics World 2.0 Showcase at IROS 2026, Four-Core Full-Stack AI Ecosystem and Industry Productivity Solutions

- Multiple EAI robots showcased at IROS 2026 further highlight the Robotics Business's "One-Brain Multi-Form Multi-Capability" EAI Robot World 2.0, with All-New Futurist drawing most attention from attendees.

- The Company engaged with various attendees including developers and ecosystem partners, along with leading universities and research institutions, with many expressing interest in future cooperation with the Robotics Business centered around the EAI Brain and Developer Platform and EAI Data Factory.

LOS ANGELES, Oct. 2, 2026 /PRNewswire/ -- FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) ("FFR" or the "Company") today highlighted the participation of the FF EAI Robotics business (the "Robotics Business") at IROS 2026 in Pittsburgh, Pennsylvania, held September 28–30, 2026. FFR has signed a non-binding term sheet to acquire the Robotics Business from Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ("FFAI") at an estimated valuation of approximately $200 million.

IROS is one of the largest and most impactful robotics research conferences worldwide. Pittsburgh is widely recognized as "a leader in robotics research" and is a city at the forefront of robotics innovation, with a strong concentration of robotics companies, research institutions, universities and industry resources.

During the event, FF showcased multiple EAI robot products, introduced the "Built in USA" Acceleration Program, and engaged with guests and partners across the global robotics, artificial intelligence, research and industry application communities through product demonstrations, hands-on experiences and discussions. The All-New Futurist drew particular attention for its mobile operation, flexible task execution and potential applications across multiple scenarios.

For the EAI Brain and Developer Platform, developers actively discussed with the company regarding robot capability development, application scenarios, and ecosystem co-creation. At the same time, FF is actively recruiting in-house development partners.

Through the EAI Data Factory, FF also engaged with potential data partners to discuss real-world data collection, data collaboration, and the role of data in continuously improving EAI robot capabilities.

The company engaged with industry professionals regarding its four Industry Productivity Solutions, which span multiple industry applications. The Research Solution attracted interest from multiple leading research institutions and universities. Participants held in-depth discussions with FF regarding robotics research, education and teaching applications, and potential opportunities for deeper cooperation.

In addition to product and ecosystem engagement, FF advanced its talent recruitment efforts during IROS 2026, seeking professionals in robotics research and development, artificial intelligence, data, and industry solutions.

FF's participation in IROS 2026 represents an important step in advancing the EAI robotics business, expanding the Company's global industry ecosystem and accelerating implementation of its "Built in USA" strategy.

"Participating in IROS 2026 gave us the opportunity to engage directly in Pittsburgh, a city at the forefront of robotics innovation, with guests, developers, industry partners, universities and research institutions from across the field," said YT Jia, Founder and Global CEO of FF. "We will continue to recruit in-house development partners, build our talent base, accelerate implementation of our 'Built in USA' strategy and bring EAI robots into more real-world industry applications."

The Company announced earlier this week that FFAI and FFR (f/k/a AIxCrypto Holdings, Inc.) entered into a non-binding term sheet contemplating FFR's proposed acquisition of FFAI's robotics assets and businesses at an estimated market valuation of approximately $200 million, with the proposed transaction intended to advance the Robotics Business toward an independent public listing.

About FF EAI Robotics Ecosystem Inc.

FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is a U.S.-based Embodied AI (EAI) robotics company that is in the process of acquiring the FF EAI Robotics business. Upon completion of the acquisition, the Company will focus on the research and development, manufacturing, commercialization, and deployment of intelligent robotic technologies, products, and industry solutions.

The Company is committed to building a "Four-Core Full-Stack" AI ecosystem covering the full lifecycle of robotics, consisting of EAI Brain & Developer Platform, EAI Devices, Industry Productivity Solutions, and EAI Data Factory. Guided by the technology and product philosophy of "One Brain, Multi-forms, Multi-capabilities," the Company aims to empower humanoid, biomimetic, and other robotic form factors through a unified EAI Brain, while continuously expanding their multi-task and multi-scenario capabilities. The ecosystem is designed to support the full robotics lifecycle, including R&D, deployment, data collection and training, operations, and commercial applications.

The FF EAI Robotics business has already achieved commercial deliveries of humanoid and biomimetic robotic products. Through its multi-form-factor robotic products, EAI technology platform, closed-loop data capabilities, and industry solutions, the business continues to advance the scaled adoption of robotics across real-world applications. The Company also operates RoboShare, a robot-sharing and services platform designed to connect robotic assets, service capabilities, customer demand, and ecosystem partners, further strengthening its robotics commercialization and service ecosystem.

For more information, visit: www.ff.com

For investor information, visit: https://investors.ff.com/

Forward-Looking Statements

This communication, including any presentation, press release, investor materials or other document of which it forms a part (this "Communication"), contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws, regarding FF EAI Robotics Ecosystem Inc. ("FFR," the "Company," "us," "our," or "we") and our industry. All statements, whether written or oral, other than statements of historical fact, including any financial projections and any statements regarding future events, our strategy, our transition to robotics operations, our plans for RoboShare, our digital asset disposition plans, the proposed acquisition of the FF EAI Robotics business, the projections referenced in this communication, our name and ticker change, any related financing, and the anticipated benefits and timing of the foregoing, our objectives, expectations, or anticipated actions or results, are forward-looking statements. You can often identify forward-looking statements by words such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely," or "continue," or the negative of these terms or other similar expressions; the absence of these words does not mean a statement is not forward-looking. These statements reflect our current expectations and projections about future events as of the date of this Communication and are necessarily based on estimates and assumptions that, while considered reasonable by management, are inherently uncertain. FFR can give no assurance that such forward-looking statements or financial projections will prove to be correct.

Actual results may differ materially from those expressed or implied by these forward-looking statements as a result of numerous risks and uncertainties, both general and specific, including, but not limited to:

The proposed transaction. The term sheet is non-binding and may not result in definitive agreements; the proposed transaction may not be approved by our special committee of independent directors, our stockholders or applicable regulators, and may not be completed on the terms described or at all; the conditions to closing and the parties' ability to satisfy them; the timing of the transaction and the costs of pursuing it; the issuance of a substantial number of shares as consideration and the resulting dilution; the proposed special stock dividend and our ability to declare and pay it; the fact that the counterparty is our controlling stockholder and the conflicts of interest inherent in the transaction; our dependence on the counterparty for transition, supply and support following any closing; the scope and enforceability of the proposed non-competition and governance arrangements; the consequences of the transaction under Nasdaq listing rules, including the possibility that we must satisfy initial listing requirements in connection with a change of control or change in the nature of our business; our ability to integrate and operate the acquired business; and the risk that the acquired business performs differently than anticipated.

Projections. The projections referenced in this communication were prepared by FFAI management for the FF EAI Robotics business on a standalone basis and do not reflect our existing business, transaction-related expenses or the combined company. We have not independently verified them or adopted them as guidance.

Verisure expands roll-out of award-winning AI-powered GuardVision® Outdoor video detector, further reinforcing its leadership in monitored home security

- Verisure's AI-powered GuardVision® Outdoor video detector extends protection beyond the home, including gardens and other outdoor areas

- The deployment of the device to new countries reinforces Verisure's leadership in applying AI to monitored security, combining advanced technology with 24/7 professional monitoring and human intervention

- New data from some of Verisure's largest markets highlights the value of proactive protection, showing that outdoor security solutions can help prevent more than half of detected intrusion attempts

- The GuardVision® Outdoor video detector is now available in 12 of Verisure's 18 markets

GENEVA, Oct. 2, 2026 /PRNewswire/ -- Verisure, the world's leading provider of professionally monitored security services by customers served, is expanding the international rollout of its AI-powered GuardVision® Outdoor video detector, bringing advanced outdoor protection and earlier threat detection to more customers. The device is now available to customers in 12 markets and offers customers the opportunity to bolster their home protection.

The GuardVision® Outdoor video detector is the world's first EN50131 Grade 2-certified device with embedded Computer Vision AI. Fully integrated into the Verisure home alarm system, it helps detect the earliest signs of a threat outside the home.

The solution is already delivering measurable results in limiting the likelihood of a home intrusion. New data from some of Verisure's largest markets highlights the value of proactive protection, showing that its outdoor security solutions can help prevent more than half of detected intrusion attempts.

Austin Lally, Verisure CEO, said: "GuardVision® Outdoor video detector is a strong example of how we are using AI to extend protection beyond the home, detect potential threats earlier and support faster intervention when it matters most. What differentiates Verisure is not technology alone, but how we combine proprietary AI, data from trillions of interactions and alarm signals, deep security experience, 24/7 professional monitoring and human expertise into a single integrated service to protect our customers better. As we continue to invest in innovation, we believe AI will further strengthen our ability to protect customers and reinforce our leadership in professionally monitored security."

A Red Dot Design Award winner, the GuardVision® Outdoor video detector provides protection night and day outside of the property. It uses HD video with infrared night vision, image capture, two-way audio, and AI tools that can distinguish between human and non-human triggers to support Verisure's 24/7 human-monitored Alarm Receiving Centre with improved verification and intervention.

The GuardVision® Outdoor video detector is now available in 12 of Verisure's 18 markets: France, Italy, Spain, Portugal, Chile, Argentina, Brazil, Sweden, Denmark, Finland, Belgium, and Germany. Norway is scheduled to launch next month, while Mexico, the Netherlands and the UK are planned for rollout next year.

€170 Million investment fuels next generation of home security

In 2025 alone, Verisure has invested approximately €170 million into its innovation and technology capabilities to deploy innovations, features, products and service enhancements. The company continues to leverage AI and has already embedded the technology in its product and service ecosystem, from cameras to motion detectors, with additional innovations such as LockGuard™ and WiFi Vision™. These solutions are delivering tangible results, helping to improve verification accuracy, accelerate response times, and strengthen intervention capabilities.

For more information about Verisure's products and services, visit www.verisure.com

Notes to editors

For Further Information, Please Contact:

Verisure Media Relations

[email protected] 

About Verisure

Verisure is the global leader in professionally monitored security services by customers served.

Every day, our dedicated teams use leading technology to Deter, Detect, Verify, and Intervene to protect ~6.4 million families and small businesses from intruders, fire, and health emergencies across 18 countries.

With over 35 years of insights, experience and innovation, Verisure is known for category-creating marketing, sales excellence, innovative products and services, and customer-centricity.

Our mission is to give our customers peace of mind by protecting what matters most to them. We believe that everyone has the right to feel safe and secure.

Thanks to a strong focus on high-quality service, we aim to have the most satisfied and loyal portfolio of customers in the industry. We estimate that we have some of the strongest growth and retention rates globally in consumer-facing services, which demonstrates our commitment to exceptional service levels and strong value proposition for our customers.

For more information: www.verisure.com

This information was brought to you by Cision http://news.cision.com.

The following files are available for download:

Share this article

"All Access with Andy Garcia" to Explore the Role of Community in Aging at Mennonite Village

Upcoming segment will examine how connections and resident-led activities shape life in a senior living community.

PORTLAND, Ore., Oct. 2, 2026 /PRNewswire/ -- All Access with Andy Garcia is scheduled to film at Mennonite Village in Albany, Oregon, on October 8, 2026, for an upcoming educational segment about the importance of community as people age. The production will look at how older adults form meaningful relationships, take part in shared activities, and find support as their needs change.

At Mennonite Village, community life takes shape in ways both planned and spontaneous. Residents bring people together around their own interests, while staff offer programs and gathering spaces that make it easy to connect. The segment will explore both the everyday friendships that develop on campus and the more structured opportunities to participate in community life.

The story of Mennonite Village dates back to the organization's founding in 1947, when Lydia Stutzman's vision for caring for older adults took shape in a home for 24 residents. Today, the Albany campus offers a range of senior living and care options. As more families consider how and where to age, the segment will explore how opportunities for friendship and belonging can enrich daily life at every stage of aging.

"As we age, the importance of community becomes even more meaningful. We all need a place where we feel connected, supported, and valued. Community reminds us that we are never meant to walk through life alone. It is through our relationships, shared experiences, and care for one another that we find purpose, belonging, and joy at every stage of life." — Diane Hood, CEO of Mennonite Village.

About All Access

"All Access with Andy Garcia" produces educational stories that introduce Public Television audiences to the people and organizations working across a range of fields. The series uses documentary storytelling to make timely topics accessible through firsthand perspectives and on-location reporting. Learn more at www.allaccessptv.com.

About Mennonite Village

Mennonite Village is a not-for-profit continuing care retirement community in Albany, Oregon. Founded in 1947, it offers independent living, assisted living, memory care and skilled nursing, with opportunities for residents to connect and participate in community life. Learn more at www.mennonitevillage.org.

SOURCE All Access

Share this article